<- Back to digest

JOA - 2026-11-05 - Journal Article; Review

Can We Target the Microbiome to Improve Outcomes in Osteoarthritis and Arthroplasty?

Pourbozorg G, Heckmann ND, Mont MA, Lieberman JR, Parvizi J

systematic reviewLOE Vn = N/AN/A

Topics

arthroplasty
PMID: 42988284DOI: 10.1016/j.arth.2026.10.044View on PubMed ->

Key Takeaway

Preclinical and observational data support a gut-joint axis in which dysbiosis exacerbates OA cartilage damage and may increase PJI susceptibility, but no clinical trial has yet validated microbiome-targeted interventions for arthroplasty outcomes.

Summary Depth

Choose how much analysis to show on this article page.

Summary

This narrative review synthesizes preclinical and emerging clinical evidence linking gut microbial composition—specifically SCFAs, bile acids, lipopolysaccharides, and tryptophan metabolites—to OA progression and PJI risk. Experimental dysbiosis models demonstrate accelerated joint damage, while microbiome modulation attenuates inflammation and preserves cartilage. Perioperative antibiotic exposure and surgical stress are identified as additional disruptors of microbial homeostasis that may impair immune resilience and elevate infection susceptibility.

Key Limitation

The entire evidence base is preclinical or observational; no randomized clinical trial has tested microbiome-targeted intervention on OA progression rate, PJI incidence, or arthroplasty outcomes.

Original Abstract

Osteoarthritis (OA) is the most prevalent degenerative joint disease and a leading cause of pain, disability, and joint arthroplasty worldwide. Despite advances in surgical technique and perioperative care, periprosthetic joint infection (PJI) remains a devastating complication associated with substantial morbidity, mortality, and healthcare costs. Increasing evidence suggests that the gut microbiome plays a central role in regulating systemic inflammation, immune competence, metabolic homeostasis, and intestinal barrier integrity, biological processes relevant to both OA progression and postoperative infection risk. Preclinical and emerging clinical studies support the existence of a gut-joint axis, whereby alterations in gut microbial composition and microbial metabolites, such as short-chain fatty acids (SCFAs), bile acids, lipopolysaccharides, tryptophan-derived metabolites, and other immunomodulatory compounds, influence joint inflammation, cartilage degeneration, and host immune responses. Experimental models demonstrate that dysbiosis exacerbates OA-related joint damage, while targeted modulation of the gut microbiome can attenuate inflammation, reduce oxidative stress, and preserve cartilage integrity. Importantly, perioperative factors such as surgical stress, antibiotic exposure, and nutritional changes may further disrupt gut microbial homeostasis, potentially impairing immune resilience and increasing susceptibility to PJI. Microbiome-targeted strategies, including dietary modification, probiotics, prebiotics, and physical activity, have shown promise in restoring microbial balance and supporting immune regulation in arthritic populations. Although most evidence remains preclinical or observational, these findings suggest that modulation of the gut microbiome represents a biologically plausible adjunctive approach for both osteoarthritis management and perioperative optimization. This review summarizes current evidence linking the gut microbiome to OA pathophysiology and surgical outcomes and evaluates the potential role of microbiome modulation in joint health optimization and PJI risk reduction. Although biologically compelling, current evidence remains largely preclinical and observational, and prospective clinical trials are required before routine implementation.